PATENT CLAIM ANALYSIS

Application Number: 16063047
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "001000"]

Abstract:
The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

Claim (Index 2):
The prophylactic and/or therapeutic agent for choroidal neovascularization according to  claim 1 , which is an oral agent.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 94.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12382702', '10685705', '13698518', '10773446', '14415994']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.763698241423138
- 35 USC 102 Novelty (BERT): 0.531263793214494
- Combined Prediction Score: 0.7404547966022736
- Mean Citation Score: 307.786744
- Max Citation Score: 317.071
- Similarity Product: 201.7743787975312

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test